(Q35967402)

11 August 2017

1 reference

title

Emerging treatments for soft tissue sarcoma of adults (English)

1 reference

11 August 2017

Werner Fahn

1

1 reference

11 August 2017

Rolf D Issels

series ordinal

2

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

Expert Opinion on Emerging Drugs

11 August 2017

published in

1 reference

11 August 2017

volume

9

1 reference

11 August 2017

issue

2

1 reference

11 August 2017

page(s)

313-334

1 reference

Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival.

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

The role of chemotherapy in the treatment of adult soft tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Current soft-tissue sarcoma classifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Gastrointestinal stromal tumors: from a surgical to a molecular approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Primary retroperitoneal sarcomas. A review of 36 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Does adjuvant radiation therapy increase loco-regional control after optimal resection of soft-tissue sarcoma of the extremities?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Should tumor depth be included in prognostication of soft tissue sarcoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

The prognostic significance of margin width for extremity and trunk sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a retrospective comparative evaluation of disease outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Ifosfamide in the adjuvant therapy of soft tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Isolated limb perfusion in the management of locally advanced extremity soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Current uses of isolated limb perfusion in the clinic and a model system for new strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

The cellular and molecular basis of hyperthermia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Hyperthermia in combined treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Increasing single epirubicin doses in advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

The use of chemotherapy in soft-tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Systemic therapy for advanced soft-tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Phase II trial of gemcitabine in advanced sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Phase II trial of paclitaxel-epirubicin in patients with recurrent soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Oral trofosfamide: an active and well-tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

A phase II trial with rosiglitazone in liposarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Preclinical and clinical results with the natural marine product ET-743

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

21 January 2018

Hyperthermia in oncology

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Soft tissue sarcomas—what is currently being done

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Mitochondrial protein import: two membranes, three translocases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Phase II study of raltitrexed (‘Tomudex’) for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Primary Adult Soft Tissue Sarcoma: Time-Dependent Influence of Prognostic Variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Postoperative Nomogram for 12-Year Sarcoma-Specific Death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

Retroperitoneal soft tissue sarcomas: a treatment challenge and a call for randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.313

21 January 2018

Identifiers

DOI

10.1517/14728214.9.2.313

1 reference

release_lqi2nodaznfclko2hcxyxwx6gm

11 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lqi2nodaznfclko2hcxyxwx6gm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference